{
  "id": 15624237,
  "title": "Merck KGaA bets on RNAi with $1.3B Silence buyout",
  "url": "https://urgent.news/2026/10/19/merck-kgaa-bets-on-rnai-with-1-3b-silence-buyout",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T13:59:52.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/merck-kgaa-rnai-13b-silence-buyout-blood-disorder-polycythemia-vera/833336/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}